Core Insights - Ruili Medical Beauty reported a revenue of 85 million RMB for the first half of 2025, a decline of 27.3% compared to the previous year, with a net loss of 8 million RMB, indicating a worsening financial situation [1] - The report highlights the brutal logic of industry reshuffling, as leading companies build competitive advantages through technological iteration and product innovation, while Ruili struggles with "revenue collapse and increasing losses" [1] - The core business of medical beauty services is experiencing persistent growth challenges, particularly in surgical projects, reflecting a consumer shift towards lighter, non-surgical services [1] Business Challenges - There is a significant disconnect between business segments, with new growth points like consulting failing to effectively fill the revenue gap [2] - The lack of synergy between upstream equipment development and terminal services hampers the conversion of R&D investments into differentiated client experiences, leading to a disconnection between technical investment and market returns [2] - The company's strategy of increasing investment in technology R&D faces severe short-term operational balance challenges, as high capital consumption pressures cash flow and profit margins [2] Strategic Focus - The strategic focus of the company remains unclear between being a "service provider" and a "technology solution provider," leading to dispersed resource allocation [2] - The reliance on traditional medical beauty service models complicates the ability to support the sustained investment intensity required for heavy asset R&D [2] - Without a clear phased implementation path, the company's transformation may remain trapped in the pain of the investment period for an extended time [2]

Group 1 - The core viewpoint of the news highlights the recent performance and financial status of Rui Li Medical Beauty, indicating a mixed performance in the stock market and financial results [1][2]. - As of August 21, the Hang Seng Index fell by 0.24%, while Rui Li Medical Beauty's stock price increased by 11.67% to HKD 0.134 per share, with a trading volume of 2.114 million shares and a turnover of HKD 280,800 [1]. - Over the past month, Rui Li Medical Beauty has seen a cumulative increase of 5.26%, and a year-to-date increase of 12.15%, which is lower than the Hang Seng Index's increase of 25.45% [1]. Group 2 - Financial data shows that for the year ending December 31, 2024, Rui Li Medical Beauty achieved total revenue of CNY 199 million, a year-on-year increase of 5.26%, while the net profit attributable to shareholders was a loss of CNY 59.212 million, a decrease of 82.43% [1]. - The gross profit margin stands at 35.82%, and the debt-to-asset ratio is 61.78% [1]. - Currently, there are no institutional investment ratings for Rui Li Medical Beauty [1]. Group 3 - Rui Li Medical Beauty is a leading provider of medical beauty services in Zhejiang Province, China, offering a wide range of services including cosmetic surgery, minimally invasive beauty services, and skin beauty services [2]. - The company also provides medical beauty management consulting services to third-party medical beauty institutions and has begun to develop a sales network for medical beauty equipment products [2]. - As of December 31, 2021, Rui Li Medical Beauty operated four private profit-making medical beauty service institutions in China, with an average industry experience of over ten years among its more than 30 practicing physicians [2].

Group 1 - The company, Ruili Medical Beauty (02135.HK), will hold a board meeting on August 29, 2025, to review and approve its interim results for the six months ending June 30, 2025, and to announce an interim dividend if applicable [1]

承董事會命 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Raily Aesthetic Medicine International Holdings Limited 瑞麗醫美國際控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2135） 董事會會議日期 瑞麗醫美國際控股有限公司（「本公司」，連同其附屬公司，統稱「本集團」）董事（「董 事」）會（「董事會」）謹此宣佈，董事會會議將於二零二五年八月二十九日（星期五） 舉行，以（其中包括）考慮及批准本集團截至二零二五年六月三十日止六個月之未 經審核中期業績及其刊發，以及考慮宣派、建議或支付股息（如有）。 瑞麗醫美國際控股有限公司 主席兼執行董事 傅海曙先生 中華人民共和國杭州，二零二五年八月十九日 於本公告日期，董事會包括執行董事傅海曙先生、宋建良先生及王瀛先生；以及獨 立非執行董事曹德全先生、楊小芬女士及劉騰先生。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Raily Aesthetic Medicine International Holdings Limited 瑞麗醫美國際控股有限公司 （於開曼群島註冊成立的有限公司） 1 （股份代號：2135） 終止合約安排 茲提述招股章程及年報。 誠如招股章程及年報所披露，杭州貝麗菲爾的業務營運涉及在中國從事醫療美容 服務業務（「受限制業務」）。由於當時生效的中國適用法律法規限制外商投資於受 限制業務，本集團於2019年1月就杭州貝麗菲爾採用了合約安排，通過合約安排使 本集團得以有效控制杭州貝麗菲爾並可獲得杭州貝麗菲爾所產生的所有經濟利益。 由於杭州貝麗菲爾決定將策略重點放在醫療美容器械產品的銷售業務上並計劃申 請醫療器械經營許可證，而本公司已根據中國法律法規終止杭州貝麗菲爾的醫療 美容服務業務並註銷杭州貝麗菲爾的醫療執業許可證，因此對於受限制業務的外 資所有權限制不再適用於杭州貝麗菲爾。董事會謹此宣佈，合約安排的 ...

Core Viewpoint - Ruili Medical Beauty (02135) anticipates a decline in revenue and an increase in losses for the six months ending June 30, 2025, compared to the same period in 2024 [1] Financial Performance - Expected revenue for the six months ending June 30, 2025, is approximately RMB 85 million, down from RMB 117 million for the same period in 2024 [1] - Anticipated loss attributable to the parent company for the six months ending June 30, 2025, is approximately RMB 8 million, compared to a loss of RMB 2 million for the same period in 2024 [1] Reasons for Loss - The board attributes the loss primarily to intense market competition, resulting in a total revenue decline of approximately RMB 32 million compared to the same period in 2024 [1] - The medical beauty services and medical beauty management consulting services segment experienced an operational loss of approximately RMB 2 million during the reporting period [1] - Share-based payment expenses during the reporting period amounted to approximately RMB 1 million [1] - Increased investment in research and development for medical device products, particularly in the indirect non-wholly owned subsidiary Suzhou Ruichuan Biomedical Technology Co., Ltd., with management and R&D expenses of approximately RMB 1 million [1]

Core Viewpoint - Ruili Medical Beauty (02135) anticipates a decline in revenue and an increase in losses for the six months ending June 30, 2025, compared to the same period in 2024 [1] Financial Performance - Expected revenue for the six months ending June 30, 2025, is approximately RMB 85 million, down from RMB 117 million for the same period in 2024 [1] - Anticipated loss attributable to the parent company for the six months ending June 30, 2025, is approximately RMB 8 million, compared to a loss of RMB 2 million for the same period in 2024 [1] Reasons for Loss - The board attributes the loss primarily to intense market competition, resulting in a total revenue decline of approximately RMB 32 million compared to the same period in 2024 [1] - The medical beauty services and medical beauty management consulting services segment is expected to incur an operational loss of approximately RMB 2 million during the reporting period [1] - Share-based payment expenses are estimated at approximately RMB 1 million during the reporting period [1] - Increased investment in research and development for medical device products, particularly in the indirect non-wholly owned subsidiary Suzhou Ruichuan Biomedical Technology Co., Ltd., with management and R&D expenses amounting to approximately RMB 1 million [1]

（於開曼群島註冊成立的有限公司） （股份代號：2135） 盈利警告 本公告乃由瑞麗醫美國際控股有限公司（「本公司」，連同其附屬公司統稱「本集團」） 根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法例 第571章證券及期貨條例第XIVA部項下之內幕消息條文（定義見上市規則）而作出。 本公司董事（「董事」）會（「董事會」）謹此通知本公司股東及有意投資者，根據對 本集團截至2025年6月30日止六個月未經審核綜合管理賬目（「未經審核管理賬目」） 的初步評估及董事會目前可獲得之資料，董事會預期本集團將錄得： 董事會認為，虧損乃主要由於以下原因： 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Raily Aesthetic Medicine International Holdings Limited 瑞麗醫美國際控股有限公司 (c) 為了加快本集團的醫療器械產品研發及生產，本集團加大對本公司間接非全 資附屬公司蘇州瑞泉生物醫藥科 ...

FF301 致：香港交易及結算所有限公司 公司名稱: 瑞麗醫美國際控股有限公司(於開曼群島註冊成立的有限公司) 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02135 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.05 USD | | 50,000,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 1,000,000,000 | USD | | 0.05 USD | | 50,000,000 | ...

Group 1 - The core viewpoint of the news highlights the recent performance of Rui Li Medical Beauty, which saw a stock price increase of 9.32% despite a cumulative decline of 6.35% over the past month, while the Hang Seng Index dropped by 1.6% [1][2] - Financial data indicates that Rui Li Medical Beauty achieved total revenue of 199 million yuan, a year-on-year increase of 5.26%, but reported a net loss of 59.21 million yuan, a significant decrease of 82.43% compared to the previous year [2] - The company's gross profit margin stands at 35.82%, with a debt-to-asset ratio of 61.78% [2] Group 2 - Currently, there are no institutional investment ratings for Rui Li Medical Beauty, and its price-to-earnings ratio is -1.03, ranking 101st in the healthcare equipment and services industry, which has an average TTM P/E ratio of -1.13 [3] - The company operates as a leading medical beauty service provider in Zhejiang, China, offering a wide range of services including cosmetic surgery, minimally invasive beauty services, and skin beauty services, along with consulting services for third-party medical beauty institutions [4] - Rui Li Medical Beauty has expanded its service network over 14 years, operating four private profit-making medical beauty service institutions in China, with over 30 practicing physicians averaging more than ten years of industry experience [4]